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Belgium (€122,737 versus €134,679), Germany (€74,880 versus
€75,734) and Spain (€44,085 versus €44,661). In France and
Italy, lifetime costs were slightly higher in the detemir arm
(€63,605 versus €63,321 and €92,036 versus €90,139, respec-
tively), leading to incremental cost-effectiveness ratios of €519
and €3256 per QALY gained, respectively. CONCLUSIONS: The
ﬁndings of this analysis suggest that, compared to NPH, insulin
detemir is likely to be dominant in Belgium, Germany and Spain
and highly cost-effective in France and Italy in patients with type
1 diabetes.
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OBJECTIVES: Canadian payers need information comparing
the cost-effectiveness of different starter insulin therapies in
order to make relevant formulary decisions and improve T2DM
patient care. Our analyses compared the cost-effectiveness of
insulin glargine with oral antidiabetic drugs (OADs) to premixed
insulin as starter insulin therapy using published clinical data
(Janka et al, 2005) and modeling the study results to a lifetime
horizon. METHODS: The CORE Diabetes Model was used to
project lifetime clinical and economic outcomes for T2DM
patients. The baseline mean HbA1c (8.85%), age, body mass
index, gender, and duration of diabetes were taken from Janka
et al. Remaining cohort characteristics, transition probabilities,
utilities, direct treatment, and complication costs (from a Cana-
dian Provincial payer perspective) were obtained from published
sources. All costs and clinical outcomes were discounted at 5%
per annum. RESULTS: Average lifetime total direct treatment
and medical costs per patient were CAN$50,328 (+1,769) for
insulin glargine with OADs and CAN$49,555 (+1,940) for pre-
mixed insulin. Discounted life expectancy and quality-adjusted
life years (QALYs) increased by 0.051(+0.286) years and
0.215(+0.216) QALYs, respectively, for insulin glargine with
OADs compared to premixed insulin. The resulting incremental
cost-effectiveness ratios (ICERs) for insulin glargine with OADs
compared to premixed insulin were CAN$15,217/life -year
gained and CAN$3,601/QALY. CONCLUSIONS: Cost-
effectiveness for insulin glargine with OADs compared to pre-
mixed insulin was primarily driven by superior HbA1c reductions
from the Janka et al. study (-1.64% for insulin glargine with
OADs vs. -1.31% for premixed insulin, p = 0.0003) The ICERs
obtained in these analyses provide evidence for the long-term
cost-effectiveness of insulin glargine with OADs compared to
premixed insulin as an initial insulin therapy for Canadians with
T2DM.
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OBJECTIVES: Canadian payers need information comparing the
cost-effectiveness of long-acting insulin analogues (LAIAs) in
order to make relevant formulary decisions. Our analyses com-
pared the cost-effectiveness of insulin glargine with insulin
detemir using published clinical data for both T1DM (Pieber
et al, 2007) and T2DM (Rosenstock et al, 2008). METHODS:
The CORE Diabetes Model was used to project lifetime clinical
and economic outcomes for T1DM and T2DM patients in sepa-
rate analyses. For T1DM, baseline mean HbA1c (8.8%), age,
body mass index, gender, and duration of diabetes were taken
from Pieber et al. For T2DM, baseline mean HbA1c (8.6%), age,
body mass index, gender, race/ethnicity, and duration of diabetes
were taken from Rosenstock et al. Remaining cohort character-
istics, transition probabilities, utilities, direct treatment, and
complication costs (from a Canadian Provincial payer perspec-
tive) were obtained from published sources for both T1DM and
T2DM analyses. All costs and clinical outcomes in both analyses
were discounted at 5% per annum. RESULTS: For T1DM,
detemir was found to have higher overall direct medical costs
(CAN$2667  4785) than glargine with a slight increase
in quality-adjusted life years (QALYs, 0.053  0.507). The
resulting incremental cost-effectiveness ratio (ICER) was
CAN$50,569/QALY for glargine compared with detemir in
T1DM. For T2DM, detemir was found to have higher overall
direct medical costs (CAN$5748  2881) than glargine with a
very slight decrease in quality-adjusted life years (QALYs,
0.005  0.259). Glargine demonstrated lower direct medical
costs and a slight improvement in QALYs compared with detemir
and is therefore a dominant strategy in T2DM. CONCLU-
SIONS: Insulin glargine demonstrated cost-effectiveness in
T1DM, consistent with current Canadian standards for health
technology assessment, and was a dominant treatment strategy in
T2DM for Canada.
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OBJECTIVES: Reduced health-related quality of life (HRQoL)
is a pronounced complication in short individuals with Growth
Hormone Deﬁciency (GHD). Current treatment options for
GHD children are limited; however, somatropin has been shown
to normalise height in childhood and adolescence compared
with no treatment. The aim of this study was to establish
whether somatropin is a cost-effective treatment for GHD
children compared with no treatment. METHODS: A cost-
effectiveness model estimated the costs and health beneﬁts over
the lifetime of GHD children. Treatment efﬁcacy was based on
Height standard deviation scores (HSDS). A Swedish health care
perspective was used. Unit costs (SEK; 2008) were obtained
from ofﬁcial sources. A 3.0% discount rate was used. Clinical
data (height, dosing and treatment duration) were obtained from
a systematic literature review (only studies with n > 300). Utility
data was derived from a published study assessing the relation
between HSDS and HRQOL. Sensitivity analyses were con-
ducted to assess the degree of uncertainty. RESULTS: Start
HSDS was -2.8 (SD 0.8) and ﬁnal HSDS was -1.5 (SD 0.8) with
somatropin treatment. Untreated children gained no HSDS. The
mean somatropin dose was 0.023 mg/kg/day over a duration of
5.1 years (SD 1.8) Over a patient’s lifetime, somatropin was
associated with a gain of 2.3 quality adjusted life years (QALYs).
Somatropin was associated with an incremental cost per QALY
of 342,592 SEK compared with no treatment. Probabilistic sen-
sitivity analysis, in which all parameters within the model were
varied, showed that there was a high probability that somatro-
pin was cost effective compared with no treatment, based on
a willingness to pay threshold of 500,000 SEK per QALY.
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CONCLUSIONS: Based on a willingness to pay threshold of
500,000 SEK per QALY, somatropin (Norditropin®) is a cost-
effective treatment for GHD children.
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OBJECTIVES: To project the cumulative incidence of end-stage
renal disease (ESRD), life expectancy (LE) and costs of treating
hypertensive patients suffering from diabetic renal disease with
either irbesartan treatment or standard hypertension treatment in
South Korea. METHODS: A Markov model that simulated pro-
gression from microalbuminuria to nephropathy, doubling of
serum creatinine, ESRD and all-cause mortality in hypertensive
patients with diabetic renal diseases was adapted to South Korea.
Three strategies were compared: 1) early use of irbesartan (ie,
start treatment in subjects with microalbuminuria); versus 2) late
use of irbesartan (ie, as from overt nephropathy); or 3) standard
hypertension care (with comparable blood pressure control).
Cumulative incidence of ESRD, LE and costs were projected for
a hypothetical cohort of 1000 subjects. Treatment-speciﬁc pro-
gression and mortality probabilities were derived from published
trials: IRMA-2 (in microalbuminuria) and IDNT (in overt neph-
ropathy). Medical management and cost data per state as well as
ESRD outcomes data were obtained from local sources. A ﬂex-
ible time horizon up to 25 years and third party payer perspective
were used. Future LE and costs were discounted at 5% yearly.
RESULTS: When compared to standard blood pressure control,
early use of irbesartan was projected to reduce the cumulative
incidence of ESRD from 23.9% to 5.5%, save KW 9,383,748
(US$8,988), and add 0.39 life years per treated patient. Late use
of irbesartan produced higher net monetary beneﬁt than control
but was dominated by early use. The superiority of early use of
irbesartan over standard care was robust for most variables,
except for the time horizon. Break-even occurred after 12 years.
CONCLUSIONS: Early use of irbesartan in hypertensive
patients with diabetic renal diseases was projected to reduce the
incidence of ESRD, extend life and reduce costs; treating patients
with irbesartan at a later stage is still beneﬁcial, but to a lesser
extent.
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OBJECTIVES: The aim of this analysis was to evaluate the
long-term clinical and economic outcomes associated with
insulin detemir and Neutral Protamine Hagedorn (NPH) insulin
in combination with mealtime insulin aspart in patients with type
1 diabetes in Sweden, based on data from a recently published
2-year, multi-national, open-label, randomized, controlled trial
(RCT). METHODS: Long-term projections of the trial results
were based on a published and validated computer model
(CORE Diabetes Model). In the trial, insulin detemir was asso-
ciated with signiﬁcant improvements in glycemic control after 24
months (HbA1c 7.36% versus 7.58%, mean difference -0.22%,
P = 0.022) and major hypoglycemic events (69% risk reduction,
P = 0.001) versus NPH. Patients treated with detemir gained less
weight (1.7 versus 2.7 kg, P = 0.024). Based on these ﬁndings,
the model was used to estimate life-expectancy, quality-adjusted
life expectancy and both direct medical costs and indirect costs
(human capital approach). Future costs and clinical beneﬁts were
discounted at 3% per annum. RESULTS: Basal-bolus therapy
with insulin detemir was projected to improve life expectancy by
approximately 0.14 years (15.02  0.19 versus 14.88  0.18
years) and quality-adjusted life expectancy by 0.53 QALYs
versus NPH (8.35  0.11 versus 7.82  0.10 QALYs). Improve-
ments in QALYs were driven by avoided or delayed diabetes-
related complications and fewer insulin side effects. Direct
medical costs over patient lifetimes were approximately SEK
26,144 higher in the insulin detemir arm (SEK 995,025 
19,580 versus 968,881  19,769), leading to an incremental
cost-effectiveness ratio of SEK 49,757 per QALY gained. Cap-
turing indirect costs associated with lost productivity led to
insulin detemir being cost saving, by approximately SEK
106,257, compared to NPH (SEK 1,964,884  45,147 versus
2,071,142  42,548). CONCLUSIONS: The ﬁndings of this
analysis suggest that, compared to NPH, insulin detemir is likely
to be highly cost-effective from a healthcare payer perspective
and dominant from a societal perspective in patients with type 1
diabetes in Sweden.
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OBJECTIVES: The aim of the analysis was to estimate the cost-
effectiveness of human insulin treatment (current standard care)
in patients with type 2 diabetes compared with biphasic insulin
aspart (BIAsp) in those treated with insulin +/- OADs, from the
perspective of third party payers in the South African private
health care sector. METHODS: Clinical outcomes and baseline
characteristics were taken from an observational study of 208
patients. A baseline mean HbA1c of 10.1% was recorded in
patient whose average age was 52.8 years. The cost-effectiveness
ratio was estimated as the incremental cost per life-year and
quality-adjusted life-year gained of BIAsp treatment. Research
was conducted to collect cost data in type 2 diabetics: resource
utilisation, treatment costs, complication costs at year 1 and
subsequent years were investigated using insurance data. Life-
years gained were based on a 30-year follow-up using a pub-
lished and validated Markov diabetes outcomes model, adjusted
for South African risks and non-speciﬁc mortality. RESULTS: In
the base-case analysis the BIAsp group had better clinical out-
comes and lower lifetime costs. The estimated discounted gain in
life-years of biphasic insulin aspart was 0.25 years, and 0.39
years with utility adjustment. The incremental cost per life-year
gained and cost per-QALY were dominant. Total costs were 7%
lower in the BIAsp group; treatment cost associated with BIAsp
was 39% higher; cost savings were greatest in patients experi-
encing cardiovascular, renal or major hypoglycaemic complica-
tions. The acceptability curve showed a 99.8% probability that
of biphasic insulin aspart is cost effective in the base case scenario
at the WHO’s suggested threshold of three times GDP per capita.
HbA1c effects were the most sensitive variable to ﬁnal outcomes.
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